Vaccine Adverse Event Tracking
VaxxTracker gives people a safe place to report symptoms they believe resulted from a vaccine.
The numbers have been interpreted from incidents reported in the VAERS database operated by the US HHS, combined with events reported at VaxxTracker.com.
Entries reported in VaxxTracker cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable.
**VAERS (Vaccine Adverse Event Reporting System) is the USA’s early warning system that monitors the safety of vaccines after they are authorized or licensed for use by the U.S. Food and Drug Administration (FDA).
** Not to be used for scientific study.
For consumers and healthcare professionals who are eligible to report to VAERS, we also recommend reporting to this system, as the centers for Disease Control and Prevention (CDC) are monitoring the adverse events reported to VAERS. All users of VaxxTracker can view charts and graphs illustrating the types of symptoms being reported, as well as the number of symptoms associated with specific vaccines and other trends
Statistics as at 14 October 2021
Options for Reporting
South African & Africa Physicians
To proceed, the following unique 6-digit code must be entered: 236888
- Confidentiality: Healthcare professionals who file reports are encouraged, but not required, to share their personal information along with their report. VaxxTracker gives healthcare providers an opportunity to do so once they have completed the case report. Any personal information shared will be stored in encrypted form only.
- Professional data management and evaluation: The back end of the website is powered by the VaxxTracker web application, which stores and manages the data securely. The data will be evaluated by professional epidemiologists and medical experts.
- Data integrity: The data will be left intact as entered. No filed records will be memory-holed because they do not fit preconceived notions or narratives.
- Language support: VaxxTracker uses an internationalized medical terminology. Chances are that healthcare professionals will be able to file a report in their own language.
- Country specific reporting: VaxxTracker is able to generate reports specific to the countries who participate in providing data. This is especially important for those countries who do not have the infrastructure to create their own vaccine adverse event reporting systems.
The purpose of VaxxTracker is to provide the global public with truthful information about adverse reactions to the COVID vaccines, in particular. To achieve this, we need your support:
- If you are a healthcare professional, and you have first-hand, accurate information about a specific occurrence of an adverse event, please file a case report.
- Regardless of whether or not you have a report to file, please help raise awareness for this site by sharing it on social media and bringing it to the attention of physicians, nurses, and other healthcare professionals who may also have first-hand information to share.
- A Vaxxtracker sample can be viewed here.
CDC Data Release - Crimes Against Humanity
Data released Friday by the Centers for Disease Control and Prevention (CDC) showed that between Dec. 14, 2020 and Oct. 8, 2021, a total of 798,636 adverse events following COVID vaccines were reported to the Vaccine Adverse Event Reporting System (VAERS). The data included a total of 16,766 reports of deaths — an increase of 456 over the previous week, and two more reports of teens who died after being vaccinated.
There were 117,399 reports of serious injuries, including deaths, during the same time period — up 5,478 compared with the previous week.
Of the 7,674 U.S. deaths reported as of Oct. 8, 11% occurred within 24 hours of vaccination, 16% occurred within 48 hours of vaccination and 28% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.
In the U.S., 400.3 million COVID vaccine doses had been administered as of Oct. 8. This includes: 232 million doses of Pfizer, 153 million doses of Moderna and 15 million doses of Johnson & Johnson (J&J).
The data come directly from reports submitted to VAERS, the primary government-funded system for reporting adverse vaccine reactions in the U.S.
Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.
Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.
As at 8 October 2021, U.S. data for 12- to 17-year-olds show:
- 21,652 total adverse events, including 1,304 rated as serious and 24 reported deaths. Two of the 24 deaths were suicides.
The most recent death involves a 15-year-old male who died six days after receiving his first dose of Pfizer’s COVID vaccine. According to his VAERS report (VAERS I.D. 1764974), the previously healthy teen complained of brief unilateral shoulder pain five days after receiving his COVID vaccine. The next day he played with two friends at a community pond, swung on a rope swing, flipped into the air, and landed in the water feet first. He surfaced, laughed and told his friends “Wow, that hurt!” He then swam toward shore underwater, as was his usual routine, but did not re-emerge.
An autopsy showed no external indication of a head injury, but there was a small subgaleal hemorrhage — a rare, but lethal bleeding disorder — over the left occiput. In addition, the boy had a mildly elevated cardiac mass, increased left ventricular wall thickness and small foci of myocardial inflammation of the lateral wall of the left ventricle with myocyte necrosis consistent with myocardial infarction.
Another recent death includes a 16-year-old female (VAERS I.D. 1757635) who complained of fatigue and died one day after receiving Pfizer’s COVID vaccine.
- 57 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases
attributed to Pfizer’s vaccine.
- 529 reports of myocarditis and pericarditis (heart inflammation) with 508 cases attributed to Pfizer’s vaccine.
- 117 reports of blood clotting disorders, with all cases attributed to Pfizer.
As at 8 October 2021, U.S. VAERS data, from Dec. 14, 2020 to Oct. 8, 2021, for all age groups combined, show:
- 19% of deaths were related to cardiac disorders.
- 54% of those who died were male, 42% were female and the remaining death reports did not include gender of the deceased.
- The average age of death was 72.7.
- Of the 2,973 cases of Bell’s Palsy reported, 51% were attributed to Pfizer vaccinations, 41% to Moderna and 8% to J&J.
- 661 reports of Guillain-Barré syndrome, with 40% of cases attributed to Pfizer, 31% to Moderna and 28% to J&J.
- 1,995 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 10,131 reports of blood clotting disorders. Of those, 4,407 reports were attributed to Pfizer, 3,654 reports to Moderna and 2,018 reports to J&J.
- 2,818 cases of myocarditis and pericarditis with 1,782 cases attributed to Pfizer, 915 cases to Moderna and 111 cases to J&J’s COVID vaccine.
FDA panel unanimously backs Moderna, J&J booster shots for older and high-risk people
According to CNBC, an advisory panel to the U.S. Food and Drug Administration (FDA) today unanimously voted to recommend J&J’s single-dose COVID vaccine to the more than 15 million Americans who have already received the first dose.
The panel recommended boosters for everyone 18 and over, at least two months after they received the first dose.
Many committee members said it should be considered a two-dose vaccine, much like the Moderna and Pfizer vaccines.
On Thursday, the FDA’s advisory panel unanimously recommended booster doses of Moderna’s COVID vaccine for Americans 65 and older and those at high risk of severe illness or occupational exposure to the virus, Reuters reported.
“The data itself is not strong, but it is certainly going in the direction that is supportable of this vote,” said Dr. Patrick Moore of the University of Pittsburgh School of Medicine. Moore said he voted in favor of Moderna boosters based largely on a “gut feeling rather than truly serious data.”
Moderna shares were up nearly 3% at $330.71 after the vote.
If the FDA signs off on the panel’s recommendation for booster doses of J&J and Moderna’s COVID vaccines, the CDC will make specific recommendations on who should get the shots. The CDC’s vaccine advisers are scheduled to meet next week.